Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AN2 Therapeutics, Inc.ANTX · Entity 1085 | Chief Accounting Officer | February 15, 2023 | February 18, 2023 |
| Aridis Pharmaceuticals, Inc.ARDS · Entity 89417 | Chief Financial Officer | February 18, 2021 | February 22, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AN2 Therapeutics, Inc.
Report date February 15, 2023 · Filed February 18, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.29 · Expires 2033-02-14 | Direct | 16,600 |
Reported balance
After 2023-02-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-15 · Grant · Acquired 16,600 · Balance 16,600 F1: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary as measured from January 1, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary as measured from January 1, 2023.
Aridis Pharmaceuticals, Inc.
Report date February 18, 2021 · Filed February 22, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $7.84 · Expires 2031-02-18 | Direct | 80,000 |
Reported balance
After 2021-02-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-02-18 · Exercise / conversion · Acquired 20,000 · Balance 80,000 F1: The stock options vest in equal installments over 48 months, beginning on February 1, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options vest in equal installments over 48 months, beginning on February 1, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 15, 2023 Filed Feb 18, 2023 00:23 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 16,600 | $0.00 Strike: $14.29 | $0.00 |
DisclosureSEC source: 0000899243-23-005550 · doc4.xml · derivative · entry 1 Nazak Michael Adrian · CIK 0001799731 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,600 Underlying: Common Stock · 16,600 shares Expires 2033-02-14 F1 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary as measured from January 1, 2023. Read SEC document |
| May 12, 2022 Filed May 17, 2022 01:21 UTC | AN2 Therapeutics, Inc. ANTX · Entity 1085 | GrantStock Option (right to buy) · Derivative | 14,300 | $0.00 Strike: $17.28 | $0.00 |
DisclosureSEC source: 0000899243-22-018287 · doc4.xml · derivative · entry 1 Nazak Michael Adrian · CIK 0001799731 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,300 Underlying: Common Stock · 14,300 shares Expires 2032-05-11 F1 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary as measured from March 25, 2022. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 20:08 UTC | Aridis Pharmaceuticals, Inc. ARDS · Entity 89417 | Exercise / conversionStock Options · Derivative | 20,000 | $0.00 Strike: $7.84 | $0.00 |
DisclosureSEC source: 0001104659-21-026339 · a4.xml · derivative · entry 1 Nazak Michael Adrian · CIK 0001799731 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 20,000 shares Expires 2031-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock options vest in equal installments over 48 months, beginning on February 1, 2021. Read SEC document |
| January 02, 2020 Filed Jan 13, 2020 16:02 UTC | Aridis Pharmaceuticals, Inc. ARDS · Entity 89417 | Exercise / conversionStock Options · Derivative | 20,000 | $0.00 Strike: $4.45 | $0.00 |
DisclosureSEC source: 0001104659-20-003445 · a4.xml · derivative · entry 1 Nazak Michael Adrian · CIK 0001799731 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 20,000 shares Expires 2030-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock options vest in equal installments over 48 months, beginning on January 2, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.